The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter
Open accessAbstract
// Samrat Roy Choudhury 1 , Yi Cui 1 , Katarzyna Lubecka 2 , Barbara Stefanska 2,3 , Joseph Irudayaraj 1,3 1 Department of Agricultural & Biological Engineering, Bindley Bioscience Centre, Purdue University, West Lafayette, IN 47907, USA 2 Department of Nutrition Science, Purdue University, West Lafayette, IN 47907, USA 3 Purdue Centre for Cancer Research, Purdue University, West Lafayette, IN 47907, USA Correspondence to: Barbara Stefanska, email: bstefanska@purdue.edu Joseph Irudayaraj, email: josephi@purdue.edu Keywords: CRISPR-dCas9, TET1, BRCA1, DNA demethylation, gene activation Received: March 10, 2016 Accepted: May 30, 2016 Published: June 23, 2016 ABSTRACT DNA hypermethylation at the promoter of tumour-suppressor genes is tightly correlated with their transcriptional repression and recognized as the hallmark of majority of cancers. Epigenetic silencing of tumour suppressor genes impairs their cellular functions and activates a cascade of events driving cell transformation and cancer progression. Here, we examine site-specific and spatiotemporal alteration in DNA methylation at a target region in BRCA1 gene promoter, a model tumour suppressor gene. We have developed a programmable CRISPR-Cas9 based demethylase tool containing the deactivated Cas9 (dCas9) fused to the catalytic domain (CD) of Ten-Eleven Translocation (TET) dioxygenase1 (TET1CD). The fusion protein selectively demethylates targeted regions within BRCA1 promoter as directed by the designed single-guide RNAs (sgRNA), leading to the transcriptional up-regulation of the gene. We also noticed the increment in 5-hydroxymethylation content (5-hmC) at the target DNA site undergoing the most profound demethylation. It confirms the catalytic activity of TET1 in TET1-dCas9 fusion proteins-mediated demethylation at these target sequences. The modular design of the fusion constructs presented here allows for the selective substitution of other chromatin or DNA modifying enzymes and for loci-specific targeting to uncover epigenetic regulatory pathways at gene promoters and other selected genomic regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Esteller, M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072067 · Cited by 3,662
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153 · cited 1×
“CRISPR tools use sgRNAs that specifically bind to the target DNA sequence, and serve as a scaffold to recruit CRISPR dependent Cas9 nuclease [33].”
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“In particular, catalytically inactive Cas9 (dCas9) in combination with single-guide RNA (sgRNA) are frequently being fused to various transcriptional factors (TFs) such as KRAB-repressors or VP64 activators to respectively inactivate (CRISPRi) or activate (CRISPRa) expression of a given gene [22, 23].”
BackgroundTet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y.-F., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,770
A gene hypermethylation profile of human cancer.
Esteller, M., Corn, P. G., Baylin, S. B., & Herman, J. G. (2001) · PubMed · Cited by 2,032
Hilton, I. B., D'Ippolito, A. M., Vockley, C. M., Thakore, P. I., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3199 · Cited by 1,885
UHRF1 Plays a Role in Maintaining DNA Methylation in Mammalian Cells
Bostick, M., Kim, J. K., Estève, P.-O., Clark, A., Pradhan, S., & Jacobsen, S. E. (2007) · Science · doi:10.1126/science.1147939 · Cited by 1,455
Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain
Guo, J. U., Su, Y., Zhong, C., Ming, G.-L., & Song, H. (2011) · Cell · doi:10.1016/j.cell.2011.03.022 · Cited by 1,360
Epigenetic reprogramming in mammals
Morgan, H. D., Santos, F., Green, K., Dean, W., & Reik, W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi114 · Cited by 1,342
Demethylation of the zygotic paternal genome
Mayer, W., Niveleau, A., Walter, J., Fundele, R., & Haaf, T. (2000) · Nature · doi:10.1038/35000656 · Cited by 1,327
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 3×
“Supplementary Figure S5: Quantitative determination of DNA demethylation level at the target CpG sites in BRCA1 promoter .”
BackgroundHigh-throughput functional genomics using CRISPR-Cas9
Shalem, O., Sanjana, N. E., & Zhang, F. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3899 · Cited by 1,233
Epigenetic reprogramming in mouse primordial germ cells
Hajkova, P., Erhardt, S., Lane, N., Haaf, T., El-Maarri, O., Reik, W., Walter, J., & Surani, M. A. (2002) · Mechanisms of Development · doi:10.1016/s0925-4773(02)00181-8 · Cited by 1,191
Cancer Incidence in BRCA1 Mutation Carriers
Thompson, D. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1358 · Cited by 1,096
Active demethylation of the paternal genome in the mouse zygote
Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., Dean, W., Reik, W., & Walter, J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00448-6 · Cited by 981
Epigenetic events in mammalian germ-cell development: reprogramming and beyond
Sasaki, H., & Matsui, Y. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2295 · Cited by 871
Uncovering the role of 5-hydroxymethylcytosine in the epigenome
Branco, M. R., Ficz, G., & Reik, W. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3080 · Cited by 766 · cited 1×
“com/oncotarget glycosylase dependent excision or DNA repair mechanisms leading to replacement with unmodified cytosines [17, 18].”
BackgroundBhutani, N., Burns, D. M., & Blau, H. M. (2011) · Cell · doi:10.1016/j.cell.2011.08.042 · Cited by 688
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation
Wu, H., & Zhang, Y. (2011) · Genes & Development · doi:10.1101/gad.179184.111 · Cited by 672
Maeder, M. L., Angstman, J. F., Richardson, M. E., Linder, S. J., Cascio, V. M., Tsai, S. Q., Ho, Q. H., Sander, J. D., Reyon, D., Bernstein, B. E., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2726 · Cited by 501
Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation
Hashimoto, H., Liu, Y., Upadhyay, A. K., Chang, Y., Howerton, S. B., Vertino, P. M., Zhang, X., & Cheng, X. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks155 · Cited by 477
THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS
Laird, P. W., & Jaenisch, R. (1996) · Annual Review of Genetics · doi:10.1146/annurev.genet.30.1.441 · Cited by 472
Kaas, G. A., Zhong, C., Eason, D. E., Ross, D. L., Vachhani, R. V., Ming, G.-L., King, J. R., Song, H., & Sweatt, J. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.08.032 · Cited by 414
RAF inhibitors that evade paradoxical MAPK pathway activation
Zhang, C., Spevak, W., Zhang, Y., Burton, E. A., Ma, Y., Habets, G., Zhang, J., Lin, J., Ewing, T., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 382
Growth retardation and tumour inhibition by BRCA1
Holt, J. T., Thompson, M. E., Szabo, C., Robinson-Benion, C., Arteaga, C. L., King, M.-C., & Jensen, R. A. (1996) · Nature Genetics · doi:10.1038/ng0396-298 · Cited by 361
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Effects of cytosine methylation on transcription factor binding sites
Medvedeva, Y. A., Khamis, A. M., Kulakovskiy, I. V., Ba-Alawi, W., Bhuyan, M. S. I., Kawaji, H., Lassmann, T., Harbers, M., Forrest, A. R., Bajic, V. B., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-119 · Cited by 250
Sp1 binding is inhibited by mCpmCpG methylation
Clark, S. J., Harrison, J., & Molloy, P. L. (1997) · Gene · doi:10.1016/s0378-1119(97)00164-9 · Cited by 207
Definition of the Landscape of Promoter DNA Hypomethylation in Liver Cancer
Stefanska, B., Huang, J., Bhattacharyya, B., Suderman, M., Hallett, M., Han, Z.-G., & Szyf, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3823 · Cited by 186
Self-citationRecognition of 5-Hydroxymethylcytosine by the Uhrf1 SRA Domain
Frauer, C., Hoffmann, T., Bultmann, S., Casa, V., Cardoso, M. C., Antes, I., & Leonhardt, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021306 · Cited by 180
Induced DNA demethylation by targeting Ten-Eleven Translocation 2 to the human ICAM-1 promoter
Chen, H., Kazemier, H. G., de Groote, M. L., Ruiters, M. H. J., Xu, G.-L., & Rots, M. G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1019 · Cited by 166
Induction of apoptosis by the tumor suppressor protein BRCA1.
Shao, N., Chai, Y. L., Shyam, E., Reddy, P., & Rao, V. N. (1996) · PubMed · Cited by 137
MicroRNA miR‐335 is crucial for the BRCA1 regulatory cascade in breast cancer development
Heyn, H., Engelmann, M., Schreek, S., Ahrens, P. R., Lehmann, U., Kreipe, H. H., Schlegelberger, B., & Beger, C. (2011) · International Journal of Cancer · doi:10.1002/ijc.25962 · Cited by 131
Fan, S., Wang, J.-A., Yuan, R., Ma, Y. X., Meng, Q., Erdos, M. R., Brody, L. C., Goldberg, I. D., & Rosen, E. M. (1998) · Oncogene · doi:10.1038/sj.onc.1202116 · Cited by 101
Synthetic epigenetics—towards intelligent control of epigenetic states and cell identity
Jurkowski, T. P., Ravichandran, M., & Stepper, P. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0044-x · Cited by 74
Wang, Z., & Chen, H. (2010) · PubMed · Cited by 71
Bai, X., Zhi, X., Zhang, Q., Liang, F., Chen, W., Liang, C., Hu, Q., Sun, X., Zhuang, Z., & Liang, T. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.048 · Cited by 55
CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors
Xu, J., Huo, D., Chen, Y., Nwachukwu, C., Collins, C., Rowell, J., Slamon, D. J., & Olopade, O. I. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0422-1 · Cited by 47
Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma
Choudhury, S. R., Cui, Y., Milton, J., Li, J., & Irudayaraj, J. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0140-y · Cited by 24
Self-citationEgr-1 regulates the transcription of the BRCA1 gene by etoposide
Shin, S. Y., Kim, C. G., & Lee, Y. H. (2013) · BMB Reports · doi:10.5483/bmbrep.2013.46.2.202 · Cited by 18
Marot, D., Opolon, P., Brailly‐Tabard, S., Elie, N., Randrianarison-Huetz, V., Connault, E., Foray, N., Feunteun, J., & Perricaudet, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302637 · Cited by 16
Cited by
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Editing DNA Methylation in the Mammalian Genome
Liu, X. S., Wu, H., Ji, X., Stelzer, Y., Wu, X., Czauderna, S., Shu, J., Dadon, D., Young, R. A., & Jaenisch, R. (2016) · Cell · doi:10.1016/j.cell.2016.08.056 · Cited by 1,224
“…our manuscript, Vojta et al. also reported that dCas9 fused with Dnmt3a can be used to methylate two human gene promoters (Vojta et al., 2016), and Xu et al. and Choudhury et al. reported that dCas9 fused with Tet1 can be used to demethylate gene promoters (Choudhury et al., 2016; Xu et al., 2016).”
Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the FMR1 Gene
Liu, X. S., Wu, H., Krzisch, M., Wu, X., Graef, J., Muffat, J., Hnisz, D., Li, C. H., Yuan, B., Xu, C., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.012 · Cited by 512
Klann, T. S., Black, J. B., Chellappan, M., Safi, A., Song, L., Hilton, I. B., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2017) · Nature Biotechnology · doi:10.1038/nbt.3853 · Cited by 447
Metadata
- Authors
- Choudhury, S. R., Cui, Y., Lubecka, K., Stefanska, B., & Irudayaraj, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-06-23
- Volume
- 7
- Issue
- 29
- Pages
- 46545-46556
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2462631977
- Cited by
- 353
- References
- 48
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.